Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.28 HKD | +0.79% | 0.00% | -12.33% |
Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.33% | 164M | |
-5.99% | 84.46B | |
+3.95% | 40.85B | |
-26.37% | 27.69B | |
+50.57% | 24.28B | |
-6.59% | 17.09B | |
-32.37% | 13.67B | |
-10.45% | 11.79B | |
-15.88% | 11.86B | |
-3.60% | 8.07B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma Announces Resignation of Wei Fu as Non-Executive Director